Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10596279 | Bioorganic & Medicinal Chemistry Letters | 2009 | 5 Pages |
Abstract
We combined the features of two structurally distinct series of SCD inhibitors that were previously reported by our group. This led to the discovery of compound CVT-12,012 which has single-digit nanomolar potency in a human HEPG2 SCD assay, 78% oral bioavailability in rats, and is preferentially distributed into liver. In a 5-day study (high sucrose diet, rat) CVT-12,012 significantly reduced liver triglycerides versus the control group (â¼50%).
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Dmitry O. Koltun, Timur M. Zilbershtein, Vasily A. Migulin, Natalya I. Vasilevich, Eric Q. Parkhill, Andrei I. Glushkov, Malcolm J. McGregor, Sandra A. Brunn, Nancy Chu, Jia Hao, Nevena Mollova, Kwan Leung, Jeffrey W. Chisholm, Jeff Zablocki,